目的构建短发夹RNA(shRNA)/mdr1的质粒表达载体并验证其体外表达效率。方法按照pSUPER的设计要求合成mdr1基因RNAi靶序列的64bp寡核苷酸序列,退火后双酶切法(BglⅡ和HindⅢ)克隆,得到质粒pSUPER-shRNA/mdr1,转染感受态大肠杆菌,筛选阳性克隆,测序证实后扩增培养并提取,然后转染融合达90%以上的HepG2/mdr1细胞,阴性载体为对照组,实时聚合酶链反应(Real-timePCR)、流式细胞术检测mdr1基因mRNA、P-gp表达、细胞耐药性等功能变化。结果成功构建质粒载体pSUPER-shRNA/mdr1,基因测序证实靶序列插入正确;HepG2/mdr1-si组mdr1基因的mRNA表达水平是耐药株HepG2/mdr1组的56分之一;HepG2/mdr1-si组细胞和阴性对照组HepG2/mdr1细胞的P-gP表达率分别为11.0%和98.6%,P〈0.05;HepG2/mdr1组细胞耐药倍数从62.5下降到1.4,相对逆转效率99.34%;细胞内DNR累积量也明显增加,与对照组比较(79.32%比37.96%),P〈0.05。结论多药耐药基因mdr1质粒表达载体pSU-PER-shRNA/mdr1能在HepG2/mdr1内稳定表达,并逆转其耐药性。
Objective To construct the expressing vector of shRNA/mdr1 and to study its reversed effect in vitro. Methods 64 bp oligonucleotides of pSUPER and the targeted sequence of siRNA/mdr1 were synthesized and annealed to form duplex strand, then were cloned into pSUPER to construct pSUPER-shRNA/mdr1 vector. Competent E. coli was transfected by vector of pSUPER-shRNA/mdr1 to screen the positive clones for sequencing and extracting plasmid. The plasmids extracted were used to transfect HepG2/mdr1 cells with control groups by negative vectors. The expression of mRNA was measured by real-time PCR, and P-glycoprotein and resistance of HepG2/mdr1 by flow cytometry. Results pSUPER-shRNA/mdr1 was established successfully and was sequenced to test its accuracy. The expression of mRNA in HepG2/mdr1-si was lower than that in HepG2/mdr1 (1-fold vs 56.30-fold,P 〈0.01 ). Compared to HepG2/mdr1, the expression of P-gp in HepG2/mdr1-si was lower (11% vs 98.6% ,P 〈 0.05 ). The sensitivity of HepG2/mdr1-si to adiramycin was higher than that of HepG2/mdr1 (62.5-fold vs 1,4-fold,P 〈0.01 ). Also, compared to controls, the accumulation of DNR in HepG2/mdr1-si was increased significandy (79.32% vs 37.96%, P 〈 0.05). Conclusion Vector of pSUPER-shRNA/mdr1 can be constructed by technique of enzymatic incision. The multidrug resistance of HepG2/mdr1 can be reversed.